Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
© 2024. The Author(s)..
BACKGROUND: Drug-induced interstitial lung disease (DIILD) is a serious adverse event potentially induced by any antineoplastic agent. Whether cancer patients are predisposed to a higher risk of DIILD after receiving immune checkpoint inhibitors (ICIs) is unknown.
METHODS: This study retrospectively assessed the cumulative incidence of DIILD in consecutive cancer patients who received post-ICI antineoplastic treatment within 6 months from the final dose of ICIs. There was also a separate control cohort of 55 ICI-naïve patients with non-small cell lung cancer (NSCLC) who received docetaxel.
RESULTS: Of 552 patients who received ICIs, 186 met the inclusion criteria. The cohort predominantly comprised patients with cancer of the lung, kidney/urinary tract, or gastrointestinal tract. The cumulative incidence of DIILD in the entire cohort at 3 and 6 months was 4.9% (95% confidence interval [CI] 2.4%-8.7%) and 7.2% (95% CI 4.0%-11.5%), respectively. There were significant differences according to cancer type (Gray's test, P = .04), with the highest cumulative incidence of DIILD in patients with lung cancer being 9.8% (95% CI 4.3%-18.0%) at 3 months and 14.2% (95% CI 7.3%-23.3%) at 6 months. DIILD was caused by docetaxel in six of these 11 lung cancer patients (54.5%). After matching, the cumulative incidence of docetaxel-induced ILD in patients with NSCLC in the post-ICI setting was higher than that in the ICI-naïve setting: 13.0% (95% CI 3.3%-29.7%) vs 4.3% (95% CI 0.3%-18.2%) at 3 months; and 21.7% (95% CI 7.9%-39.9%) vs 4.3% (95% CI 0.3%-18.2%) at 6 months. However, these were not significant differences (hazard ratio, 5.37; 95% CI 0.64-45.33; Fine-Gray P = .12).
CONCLUSIONS: Patients with lung cancer were at high risk of developing DIILD in subsequent regimens after ICI treatment. Whether NSCLC patients are predisposed to additional risk of docetaxel-induced ILD by prior ICIs warrants further study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Respiratory research - 25(2024), 1 vom: 10. Jan., Seite 25 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kitahara, Yoshihiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
15H5577CQD |
|---|
| Anmerkungen: |
Date Completed 12.01.2024 Date Revised 13.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12931-024-02683-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366910868 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366910868 | ||
| 003 | DE-627 | ||
| 005 | 20240114234852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-024-02683-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1258.xml |
| 035 | |a (DE-627)NLM366910868 | ||
| 035 | |a (NLM)38200501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kitahara, Yoshihiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2024 | ||
| 500 | |a Date Revised 13.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Drug-induced interstitial lung disease (DIILD) is a serious adverse event potentially induced by any antineoplastic agent. Whether cancer patients are predisposed to a higher risk of DIILD after receiving immune checkpoint inhibitors (ICIs) is unknown | ||
| 520 | |a METHODS: This study retrospectively assessed the cumulative incidence of DIILD in consecutive cancer patients who received post-ICI antineoplastic treatment within 6 months from the final dose of ICIs. There was also a separate control cohort of 55 ICI-naïve patients with non-small cell lung cancer (NSCLC) who received docetaxel | ||
| 520 | |a RESULTS: Of 552 patients who received ICIs, 186 met the inclusion criteria. The cohort predominantly comprised patients with cancer of the lung, kidney/urinary tract, or gastrointestinal tract. The cumulative incidence of DIILD in the entire cohort at 3 and 6 months was 4.9% (95% confidence interval [CI] 2.4%-8.7%) and 7.2% (95% CI 4.0%-11.5%), respectively. There were significant differences according to cancer type (Gray's test, P = .04), with the highest cumulative incidence of DIILD in patients with lung cancer being 9.8% (95% CI 4.3%-18.0%) at 3 months and 14.2% (95% CI 7.3%-23.3%) at 6 months. DIILD was caused by docetaxel in six of these 11 lung cancer patients (54.5%). After matching, the cumulative incidence of docetaxel-induced ILD in patients with NSCLC in the post-ICI setting was higher than that in the ICI-naïve setting: 13.0% (95% CI 3.3%-29.7%) vs 4.3% (95% CI 0.3%-18.2%) at 3 months; and 21.7% (95% CI 7.9%-39.9%) vs 4.3% (95% CI 0.3%-18.2%) at 6 months. However, these were not significant differences (hazard ratio, 5.37; 95% CI 0.64-45.33; Fine-Gray P = .12) | ||
| 520 | |a CONCLUSIONS: Patients with lung cancer were at high risk of developing DIILD in subsequent regimens after ICI treatment. Whether NSCLC patients are predisposed to additional risk of docetaxel-induced ILD by prior ICIs warrants further study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Docetaxel | |
| 650 | 4 | |a Drug-induced pneumonitis | |
| 650 | 4 | |a Immune checkpoint inhibitor | |
| 650 | 4 | |a Interstitial lung disease | |
| 650 | 4 | |a Pneumonitis | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Docetaxel |2 NLM | |
| 650 | 7 | |a 15H5577CQD |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Inoue, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yasui, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Karayama, Masato |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Yuzo |e verfasserin |4 aut | |
| 700 | 1 | |a Hozumi, Hironao |e verfasserin |4 aut | |
| 700 | 1 | |a Furuhashi, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Enomoto, Noriyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Fujisawa, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Funai, Kazuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Honda, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Misawa, Kiyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Miyake, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Hiroya |e verfasserin |4 aut | |
| 700 | 1 | |a Inui, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Suda, Takafumi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d 2000 |g 25(2024), 1 vom: 10. Jan., Seite 25 |w (DE-627)NLM115627553 |x 1465-993X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:10 |g month:01 |g pages:25 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12931-024-02683-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 1 |b 10 |c 01 |h 25 | ||